Faculty Opinions recommendation of Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study.

Author(s):  
Jagmeet Singh ◽  
Dan Blendea
2010 ◽  
Vol 6 (3) ◽  
pp. 60
Author(s):  
Richard Schilling ◽  

Atrial fibrillation (AF) is linked to an increased risk of adverse cardiovascular events. While rhythm control with antiarrhythmic drugs (AADs) is a common strategy for managing patients with AF, catheter ablation may be a more efficacious and safer alternative to AADs for sinus rhythm control. Conventional catheter ablation has been associated with challenges during the arrhythmia mapping and ablation stages; however, the introduction of two remote catheter navigation systems (a robotic and a magnetic navigation system) may potentially overcome these challenges. Initial clinical experience with the robotic navigation system suggests that it offers similar procedural times, efficacy and safety to conventional manual ablation. Furthermore, it has been associated with reduced fluoroscopy exposure to the patient and the operator as well as a shorter fluoroscopy time compared with conventional catheter ablation. In the future, the remote navigation systems may become routinely used for complex catheter ablation procedures.


ESC CardioMed ◽  
2018 ◽  
pp. 2173-2177
Author(s):  
Chawannuch Ruaengsri ◽  
Matthew R. Schill ◽  
Richard B. Schuessler ◽  
Ralph J. Damiano

Surgical ablation for atrial fibrillation was introduced in 1987 and has since become well established as a treatment option for patients with symptomatic atrial fibrillation refractory to antiarrhythmic drugs and/or catheter ablation or patients who are having concomitant cardiac surgical procedures. The Cox–Maze procedure has been improved upon by modern variations using ablation devices. More limited ablation procedures and hybrid procedures have been introduced, but their efficacy requires further investigation.


Author(s):  
Mazhar Warraich ◽  
Christina Peter ◽  
Mahmood Ahmad ◽  
Shazaib Sheikh ◽  
George R Abraham ◽  
...  

Author(s):  
Miruna A. Popa ◽  
Marc Kottmaier ◽  
Elena Risse ◽  
Marta Telishevska ◽  
Sarah Lengauer ◽  
...  

Abstract Background Early recurrence of atrial tachyarrhythmia (ERAT) is common after radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF), but its clinical significance in patients with persistent AF remains unclear. We sought to determine the predictive value of ERAT for rhythm outcome after RFCA for persistent AF. Methods The study included 207 consecutive patients (mean age 66.4 ± 10.7 years, male 66.2%) with persistent and long-standing persistent AF undergoing de novo pulmonary vein isolation (± atrial substrate ablation). All patients remained off antiarrhythmic drugs. ERAT was defined as any atrial arrhythmia ≥ 30 s occurring within the first 30 days. Late recurrence (LR) was determined during follow-up visits scheduled 1, 3, 6 and 12 months post-ablation using 7-day Holter ECGs. Results ERAT occurred in 143/207 (69.1%) patients as AF (60%) or atrial tachycardia (40%) and was persistent in 82% of cases. During a median follow-up of 22.2 months, LR occurred significantly more often in patients with ERAT than in patients without ERAT (92.3 vs. 43.8%, P < 0.001). The only independent predictors for LR were ERAT (OR 16.8, 95% CI 6.184–45.797, P < 0.001) and intraprocedural termination to sinus rhythm (OR 0.052, 95% CI 0.003–0.851, P = 0.038). Extending the blanking period from 30 to 90 days did not impact LR rates. Conclusion ERAT following ablation of persistent AF is strongly associated with late arrhythmia recurrence, which challenges the assumption that ERAT represents merely a transient phenomenon. While limiting the blanking period to 30 days seems justified, the benefit of early re-ablations remains to be addressed in future studies. Graphic abstract


2011 ◽  
Vol 34 (1) ◽  
pp. 23-29 ◽  
Author(s):  
Juan F. Viles-Gonzalez ◽  
Valentin Fuster ◽  
Jonathan Halperin ◽  
Hugh Calkins ◽  
Vivek Y. Reddy

Sign in / Sign up

Export Citation Format

Share Document